Label-free ADAM10 capacitive assay for the early diagnosis of Alzheimer's disease
Carregando...
Arquivos
Fontes externas
Fontes externas
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Tipo
Artigo
Direito de acesso
Arquivos
Fontes externas
Fontes externas
Resumo
This study demonstrates a quantum capacitance-based approach using a peptide-redox-active interface modified with Ab1 and Ab2 ADAM10 isoform antibodies for the development of label-free and point-of-care assays that enable high-accuracy quantification of the target analyte in plasma samples. The sensitivity of the quantum capacitance to changes in interface energy upon analyte binding suggests significant potential for creating miniaturized diagnostic devices for non-communicable diseases, including Alzheimer's disease.
Descrição
Palavras-chave
ADAM10 biosensors, ADAM10 plasma assays, Alzheimer's disease, Label-free capacitive biosensors, Quantum capacitance
Idioma
Inglês
Citação
Sensors and Actuators B: Chemical, v. 427.
